Phase 3 HR+/HER2- Breast Cancer trials recruiting now

All HR+/HER2- Breast Cancer trials, every phase

Other phases for HR+/HER2- Breast Cancer

Phase 3 HR+/HER2- Breast Cancer trials

• Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
  NCT06447623 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
  NCT07492641 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
  NCT07242352 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
  NCT06977893 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 13 locations
• Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
  NCT07106632 · Phase: Phase 3 · Ages: 35 Years to 45 Years · Sex: Female · 105 locations

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.